| Literature DB >> 15755512 |
Martin H Kropff1, Guido Bisping, Doris Wenning, Sarah Volpert, Joëlle Tchinda, Wolfgang E Berdel, Joachim Kienast.
Abstract
Fifteen patients with advanced multiple myeloma were scheduled to receive bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 every 3 weeks for eight cycles in combination with dexamethasone. One patient (7%) achieved a complete response, 10 (67%) a partial response, and one (7%) a minor response (MR) resulting in an overall response rate (> or = MR) of 80% (9/9 with > or = 2nd untreated and 3/6 with refractory relapse). Responses occurred after a median of 3 weeks and were independent of conventional prognostic parameters including deletion of chromosome 13. Adverse events, mainly myelosuppression, neuropathy and fatigue, were manageable.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15755512 DOI： 10.1016/j.leukres.2004.11.004
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156